Inhaled administration of tobramycin assures high concentrations in cystic fibrotic lungs, improving the therapeutic ratio over that of parenteral tobramycin levels, particularly against Pseudomonas aeruginosa. Conventional Clinical and Laboratory Standards Institute (CLSI; formerly National Committee for Clinical Laboratory Standards) breakpoints only consider parenteral levels and do not take...

www.eymj.org Lee, et al. reported the prevalence and antibiotic susceptibility of Mycoplasma hominis and Ureaplasma urealyticum in pregnant women. They used Mycoplasma IST-2 kit (bioMerieux, Marcy-l’Etoile, France) for the identification and antibiotics susceptibility testing. In the article, the breakpoints were defined as tetracycline S≤4, R≥8; doxycycline S≤4, R≥8; azithromycin S≤0.12, R≥4; ...

SUSCEPTIBILITY TESTS Antibacterial susceptibility testing is not necessary for every case in veterinary medicine because the majority of cases can be treated empirically. But performed properly, antibiotic susceptibility results are helpful to select proper antibacterial therapy for patients with refractory infections, seriously ill animals, or when resistant strains of bacteria are suspected. ...

T he Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) has been publishing standards and guidelines for clinicallaboratory procedures since the early 1970s. At least six documents detail proper specimen-collection and -processing procedures; most have been recently revised. The revisions reflect significant changes that all specimen-collection personnel, regardless of their pro...

BACKGROUND In several European Countries, by the end of 2012, CLSI guidelines will be replaced by EUCAST. We compared antimicrobial susceptibility results of a large number of respiratory pathogens using both EUCAST and previously adopted CLSI criteria to evaluate the impact on susceptibility patterns and the possible consequences that could occur in clinical practice due to this replacement.Fo...

We prospectively determined the antifungal susceptibility of yeast isolates causing fungemia using the Etest on direct blood samples (195 prospectively collected and 133 laboratory prepared). We compared the Etest direct (24 h of incubation) with CLSI M27-A3 and the standard Etest methodologies for fluconazole, voriconazole, posaconazole, isavuconazole, caspofungin, and amphotericin B. Strains ...

We investigated the clinical usefulness of the revised 2010 Clinical and Laboratory Standards Institute (CLSI) breakpoints for Escherichia coli and Klebsiella spp. Of 2,623 patients with bacteremia caused by E. coli or Klebsiella spp., 573 who had been treated appropriately with cephalosporin based on the CLSI 2009 guidelines were enrolled. There were no differences in the rates of treatment fa...

BACKGROUND An observational study was conducted in 12 European countries by the European Federation of Clinical Chemistry and Laboratory Medicine Working Group for the Preanalytical Phase (EFLM WG-PRE) to assess the level of compliance with the CLSI H3-A6 guidelines. METHODS A structured checklist including 29 items was created to assess the compliance of European phlebotomy procedures with t...

BACKGROUND Voriconazole is a first-line agent for the treatment of invasive pulmonary aspergillosis (IPA). There are increasing reports of Aspergillus fumigatus isolates with reduced susceptibility to voriconazole. METHODS An in vitro dynamic model of IPA was developed that enabled simulation of human-like voriconazole pharmacokinetics. Galactomannan was used as a biomarker. The pharmacodynam...